31 Mar Topiramate – Risk of Neurodevelopmental Disorders
Posted at 15:34h
in
In collaboration with the South African Health Products Regulatory Authority (SAHPRA), Ranbaxy Pharmaceuticals (Pty) Ltd South Africa, Zydus Healthcare SA (Pty) Ltd and, Trinity Pharma (Pty) Ltd wish to inform you about the risk of neurodevelopmental disorders in the children born to women exposed to topiramate during pregnancy.
The Professional Information (PI) and Patient Information Leaflet (PIL) will be updated accordingly.
Download latest version
Document Number:
DHCPL
Version:
1
Date Updated:
31/03/2025
File Type:
pdf
Category:
Communication To Health Care Professionals